FibroGen (FGEN) Receiving Somewhat Favorable Media Coverage, Study Finds

News articles about FibroGen (NASDAQ:FGEN) have trended somewhat positive recently, according to Accern. The research group rates the sentiment of news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. FibroGen earned a coverage optimism score of 0.14 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 47.3382294491004 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

These are some of the media stories that may have effected Accern Sentiment’s analysis:

How to Become a New Pot Stock Millionaire

Shares of FGEN stock opened at $50.50 on Wednesday. FibroGen has a 52 week low of $22.75 and a 52 week high of $63.00. The company has a debt-to-equity ratio of 0.17, a quick ratio of 9.70 and a current ratio of 9.70. The stock has a market capitalization of $4,228.42, a P/E ratio of -28.53 and a beta of 1.76.

A number of analysts recently weighed in on the stock. TheStreet upgraded shares of FibroGen from a “d” rating to a “c-” rating in a research report on Tuesday, February 27th. ValuEngine downgraded shares of FibroGen from a “hold” rating to a “sell” rating in a research report on Thursday, March 1st. Leerink Swann reiterated an “outperform” rating and issued a $88.00 price target (up from $80.00) on shares of FibroGen in a research report on Wednesday, February 28th. Zacks Investment Research downgraded shares of FibroGen from a “hold” rating to a “sell” rating in a research report on Monday, March 5th. Finally, BidaskClub upgraded shares of FibroGen from a “sell” rating to a “hold” rating in a research report on Thursday, December 21st. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $66.67.

In related news, VP Pat Cotroneo sold 42,026 shares of the stock in a transaction that occurred on Thursday, March 15th. The stock was sold at an average price of $52.85, for a total transaction of $2,221,074.10. Following the completion of the sale, the vice president now directly owns 168,334 shares of the company’s stock, valued at approximately $8,896,451.90. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider K Peony Yu sold 9,891 shares of the stock in a transaction that occurred on Wednesday, March 14th. The stock was sold at an average price of $53.20, for a total value of $526,201.20. Following the sale, the insider now directly owns 128,333 shares of the company’s stock, valued at $6,827,315.60. The disclosure for this sale can be found here. Over the last three months, insiders have sold 483,335 shares of company stock valued at $25,457,790. 13.60% of the stock is owned by company insiders.

COPYRIGHT VIOLATION WARNING: “FibroGen (FGEN) Receiving Somewhat Favorable Media Coverage, Study Finds” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://www.com-unik.info/2018/03/21/fibrogen-fgen-receiving-somewhat-favorable-media-coverage-study-finds.html.

About FibroGen

FibroGen, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit